SeaStar Medical Q4 2025 revenue $420K; net loss narrows to $2.9M; cash grows to $12M

SeaStar Medical Holding Corp

Net revenue Q4 2025 $420K (vs $67K Q4 2024); full year $1.2M (vs $135K).
Net loss Q4 2025 $2.9M ($0.80/share) vs $4.4M ($8.98/share) Q4 2024; cash $12.0M (up from $1.8M).
QUELIMMUNE expanded to 16 children's hospitals; SAVE Registry enrollment completed (50 patients).
NEUTRALIZE-AKI trial >50% enrolled (181/339); modular PMA submission for adult AKI initiated.
Guides 2026 net product revenue ~$2M; plans to add 15 more hospital sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.